Retatrutide vs Wegovy

Summary: Wegovy is on pharmacy shelves today and produces about 15% mean weight loss; retatrutide is investigational with roughly 24% loss in Phase 2 and 28.7% in TRIUMPH-4 Phase 3, but you cannot buy it legally yet.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: this is not a real choice for patients today. Wegovy is the FDA approved semaglutide product you can fill at any US pharmacy with a prescription, and it produced about 14.9% mean weight loss at 68 weeks in the STEP-1 trial ^[1]. Retatrutide is an Eli Lilly investigational triple agonist that has produced about 24.2% mean weight loss at 48 weeks in Phase 2 ^[2] and a reported 28.7% in the TRIUMPH-4 Phase 3 readout ^[4], but it is not approved, not for sale, and not legally prescribable outside a clinical trial. So when someone asks "retatrutide vs Wegovy," the honest framing is one available drug versus one future drug.

Below is the comparison anyway, because the efficacy gap is large enough that knowing what is coming changes how you think about the drug you can take right now.

The fast comparison

That is the snapshot. Everything below is why each row says what it says.

Approval status: one is real, one is not

Wegovy is the brand name for semaglutide 2.4 mg, approved by the FDA in June 2021 for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition ^[3]. It is the same molecule as Ozempic, just at a higher maximum dose and labeled for obesity rather than type 2 diabetes. In 2024 the FDA expanded the label to include reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity, based on the SELECT trial.

Retatrutide has none of that. As of May 2026 it sits in Phase 3 trials under Lilly's TRIUMPH program. TRIUMPH-1 enrolled adults with obesity, TRIUMPH-2 added type 2 diabetes, TRIUMPH-3 looked at obesity plus cardiovascular disease, and TRIUMPH-4 reported topline results in early 2026 showing roughly 28.7% mean weight loss at the top dose ^[4]. None of that data has produced an FDA approval. There is no NDA decision date that has been publicly committed to. There is no legal channel for a US patient to be prescribed retatrutide today outside of trial enrollment.

Mechanism: mono agonist vs triple agonist

Wegovy hits one receptor. Semaglutide binds the GLP-1 receptor in the hypothalamus, slows gastric emptying, blunts post-meal glucose excursions, and reduces appetite signaling. That single-receptor action is enough to produce the largest weight loss of any approved monotherapy before tirzepatide arrived. It also produces enough cardiovascular benefit that SELECT showed a 20% reduction in major adverse cardiac events.

Retatrutide hits three. The GLP-1 component covers the same appetite and satiety axis as semaglutide. The GIP component is the same receptor tirzepatide added, which appears to amplify GLP-1 effects and may reduce nausea at equivalent weight loss. The glucagon component is the new piece. Glucagon receptor agonism raises resting energy expenditure, drives hepatic fat oxidation, and increases heart rate by roughly 5 to 8 beats per minute. That is why retatrutide produces larger reductions in liver fat than semaglutide does at any comparable dose, and it is also why the safety story is not finished yet. Glucagon receptor effects on the heart, on glucose regulation in non-diabetic patients, and on long-term metabolic adaptation are still being characterized.

For the retatrutide vs semaglutide weight loss question, the mechanism is the explanation. Three hormone pathways do more than one. The cost of that extra activity is more biological uncertainty, which is exactly what Phase 3 trials are meant to resolve.

Efficacy: the 10-point gap

STEP-1 enrolled 1,961 adults without diabetes who had a BMI of 30 or higher. After 68 weeks of weekly semaglutide 2.4 mg plus lifestyle intervention, mean weight loss was 14.9% from baseline versus 2.4% on placebo ^[1]. About half the treatment group hit 15% or more. That is the result that turned Wegovy into a multi-billion dollar product and set the bar everything since then is measured against.

Retatrutide's Phase 2 trial published in NEJM in 2023 enrolled 338 adults with obesity. After 48 weeks, the 12 mg weekly dose produced 24.2% mean weight loss ^[2]. Patients on the highest dose were still losing weight at the trial end, meaning the curve had not yet plateaued. TRIUMPH-4, Lilly's Phase 3 readout in early 2026, reported approximately 28.7% mean weight loss at 76 weeks at the top dose, the highest mean reduction ever recorded for a pharmacological obesity treatment ^[4].

The gap is not subtle. Wegovy is roughly 15%, retatrutide is roughly 25 to 28%. For context, the best-performing bariatric surgery (Roux-en-Y gastric bypass) produces about 25 to 30% sustained weight loss. Retatrutide would be the first injectable to land in the same range as surgery. That comparison is also why the retatrutide vs bariatric surgery question keeps showing up: a drug that approaches surgical efficacy without anatomical permanence is a genuinely new category.

Liver fat is a separate axis. Retatrutide's Phase 2 trial showed about 42% relative reduction in hepatic fat content on MRI-PDFF, compared with roughly 30 to 35% for semaglutide in comparable populations ^[2]. That difference comes from glucagon's direct effect on hepatic lipid oxidation, and it makes retatrutide particularly interesting for non-alcoholic steatohepatitis, where semaglutide has shown moderate but not dramatic effects.

Safety: the known versus the still-being-learned

Wegovy's safety profile is the most mapped of any obesity drug on the market. Five years of post-marketing data, millions of patient-weeks of exposure, and the SELECT cardiovascular outcomes trial covering about 17,000 patients ^[3]. The known issues: GI side effects (nausea, vomiting, diarrhea, constipation) in roughly 40 to 70% of patients during titration, mostly resolving by week 8 to 12; gallbladder events at about 2 to 3%; rare pancreatitis; a boxed warning for medullary thyroid carcinoma based on rodent data with no confirmed human cases. Most discontinuations happen in the first three months and they happen for tolerability, not safety.

Retatrutide's side effect profile in Phase 2 looks structurally similar to other incretins, but the GI rates at the top dose run higher. In the 12 mg arm, nausea hit roughly 50% and vomiting around 30%, with discontinuation for adverse events around 16% ^[2]. That is meaningfully higher than what semaglutide produces at its therapeutic dose. Whether Phase 3 reproduces those numbers depends on how Lilly titrates, and TRIUMPH-1 used a slower escalation than the original Phase 2 design specifically to soften the GI curve.

The glucagon-receptor uncertainties are the part nobody can fully answer until long-term data lands. Resting heart rate goes up. Glucose regulation in non-diabetic patients needs to stay clean across years, not months. Bone mineral density on rapid weight loss is a real concern with any drug in this efficacy range. Lean mass preservation is the open question for the entire field, and the cardio vs weights on retatrutide question, which is really about how to protect muscle during a 25%-plus weight loss, is the same question every patient on tirzepatide or future triples will need to answer with resistance training and protein intake.

Cost: priced vs not-yet-priced

Wegovy's US list price sits around $1,350 per month. With commercial insurance that covers obesity treatment, copays often drop to $0 to $200. Without coverage, Lilly's competitor Zepbound has anchored a cash-pay vial market at around $349 to $499 per month, and Novo has responded with direct-to-consumer pricing on Wegovy at similar levels in 2025 and 2026.

Retatrutide has no commercial price because it is not commercial. If you want a guess, the historical Lilly pattern is to price new obesity products competitively with Wegovy on a per-month basis at launch, with patient assistance programs to soften the blow for those without coverage. The cost question is irrelevant until approval lands, which leads to the next section.

When retatrutide might launch

Lilly has not committed publicly to a target FDA filing date. The TRIUMPH program needs to complete its Phase 3 endpoints, the data needs to be submitted, and the FDA review timeline for a priority-reviewed obesity drug is roughly six to ten months. Working backward from the typical industry pattern and the TRIUMPH-4 topline already reported, an optimistic case is an FDA decision in late 2026 or 2027. A realistic case probably lands in 2027 or 2028. Lilly's tirzepatide approval timeline, from Phase 3 completion to obesity indication approval, is the relevant precedent, and it took roughly two years from pivotal data to label.

What this means for patients today

If you are deciding what to take right now, retatrutide is not on the menu. The real choice in 2026 is semaglutide (Wegovy or Ozempic), tirzepatide (Zepbound or Mounjaro), or older options like liraglutide (Saxenda) and phentermine. Tirzepatide produces about 20 to 22% mean weight loss in SURMOUNT trials, which is the closest currently available drug to retatrutide's projected efficacy. If you are responding to semaglutide and tolerating it, there is no reason to wait. If you are stuck, tirzepatide is the upgrade path that does not require a regulatory miracle.

The retatrutide vs orforglipron question is also worth flagging because orforglipron is Lilly's oral GLP-1 candidate, not an injectable, and it would compete with semaglutide rather than retatrutide. The retatrutide vs cagrisema question (Novo's amylin + semaglutide combination) and the retatrutide vs survodutide question (Boehringer's GLP-1/glucagon dual) are the more direct comparisons inside the next-generation obesity drug class. All three are in late-stage trials, and all three will eventually be sorted by Phase 3 readouts and CV outcomes data rather than by Phase 2 hype.

Myths vs facts

A few of the things that get repeated about this comparison need correction.

The claim that "retatrutide replaces Wegovy" is wrong because retatrutide does not yet exist as a prescribable product. The claim that "retatrutide is just a stronger Wegovy" is wrong because the mechanism is fundamentally different (three receptors, not one). The claim that "retatrutide is safer than Wegovy" is wrong because we do not have the long-term safety data to make that comparison yet, and the glucagon component introduces effects semaglutide simply does not have. The claim that you can buy "real retatrutide" online for research use is technically true that vials exist, but those vials are not the compound being tested in TRIUMPH and they carry every risk of any unregulated injectable.

Common questions

Is retatrutide better than Wegovy for weight loss?

On mean weight loss, yes. Retatrutide produced about 24% loss in Phase 2 and 28.7% in TRIUMPH-4 Phase 3, versus 14.9% for Wegovy in STEP-1. But retatrutide is not approved or available outside clinical trials.

When will retatrutide be FDA approved?

Lilly has not committed to a date. Based on the TRIUMPH Phase 3 program timeline and FDA review norms, an approval in 2027 or 2028 is the realistic expectation.

Can I get retatrutide instead of Wegovy right now?

No. Retatrutide is investigational. The only legal way to access it is enrollment in a Lilly-sponsored clinical trial. Anything else marketed as retatrutide is not the trial compound.

Is retatrutide stronger than tirzepatide?

In cross-trial comparison, yes. Retatrutide's 24 to 28% mean loss exceeds tirzepatide's 20 to 22% in SURMOUNT-1. Head-to-head trials would be needed to confirm, and none have been published.

How does retatrutide compare to semaglutide on liver fat?

Retatrutide's Phase 2 trial showed about 42% relative reduction in liver fat on MRI-PDFF, versus roughly 30 to 35% for semaglutide. The glucagon receptor component drives hepatic fat oxidation directly.

How does retatrutide compare to Ozempic, Mounjaro, or Zepbound?

Ozempic and Wegovy are both semaglutide. Mounjaro and Zepbound are both tirzepatide. Retatrutide is more potent than all four on mean weight loss data, but it is not available as a prescription product.

Are retatrutide side effects worse than semaglutide?

At the top dose (12 mg weekly), GI side effects ran higher in retatrutide's Phase 2 than in semaglutide trials, with about 16% discontinuing for adverse events. Heart rate also rises a few beats per minute due to glucagon activity.

Is retatrutide a replacement for bariatric surgery?

Potentially. Surgery produces 25 to 30% sustained weight loss and retatrutide's Phase 3 results approach that range. The trade-off is lifetime dosing versus a one-time procedure, and long-term durability data on retatrutide does not yet exist.

Will retatrutide be cheaper or more expensive than Wegovy?

Unknown. Lilly's historical pricing pattern for new obesity drugs anchors near competitor list prices at launch, then adjusts via direct-to-consumer programs. Plan on Wegovy-comparable pricing in the first year.

Can I combine retatrutide with phentermine, liraglutide, or another GLP-1?

No. There is no clinical evidence for stacking incretins with each other or with sympathomimetic appetite suppressants, and the side effect risk rises sharply. Single-agent therapy is the studied path.

Bottom line

Wegovy is the drug you can take. Retatrutide is the drug Lilly is building. The efficacy gap between the two is real and large, but it is not actionable in 2026. Choose from the FDA approved options that exist, follow the Phase 3 readouts as they land, and revisit this comparison the year retatrutide actually gets a label.